newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment